CLINICAL TRIALS PROFILE FOR FOSPHENYTOIN SODIUM

All Clinical Trials for fosphenytoin sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02920060 ↗	Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus	Completed	Institute of Medical Sciences of the Banaras Hindu University (BHU),India	Phase 2	2015-01-01	This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus.
NCT02920060 ↗	Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus	Completed	Banaras Hindu University	Phase 2	2015-01-01	This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus.
NCT05480553 ↗	A Phase 3 Study of NPC-06 in Patients With Pain Associated With Acute Herpes Zoster	Not yet recruiting	Nobelpharma	Phase 3	2022-08-15	To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in patients with pain associated with acute herpes zoster in a placebo-controlled, double-blind, parallel-group, comparative manner.
NCT06067412 ↗	Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health,Faisalabad	Completed	Shaheed Zulfiqar Ali Bhutto Medical University	N/A	2022-08-01	Status epilepticus is the second most common neurologic emergency in children. Morbidity and mortality are considerable; thus, timely termination of convulsive status epilepticus is the primary goal of management to avoid these risks Our objective was to compare the efficacy of phenytoin and Levetiracetam in status epilepticus in children. This study was done in the pediatric emergency department of Children Hospital Faisalabad. A total of 70 patients were randomly allocated to one of the groups by a computer-generated random number table according to their admission in an emergency. Children in group A were given levetiracetam. Children in group B were given I/V phenytoin. For both groups if seizures recurred after the first loading dose an additional 10mg/kg of the same drug was given over 10 minutes. The patients were monitored to see whether there was any recurrence of seizure activity in the subsequent 24 hours. Seizure control was defined as the absence of seizure within 24 hours after the initial loading of the drug.

Clinical Trial Conditions for fosphenytoin sodium

Condition Name

Condition Name for fosphenytoin sodium
Intervention	Trials
Acute Pain in Herpes Zoster	1
Grand Mal Status Epilepticus	1
Status Epilepticus	1

Condition MeSH

Condition MeSH for fosphenytoin sodium
Intervention	Trials
Status Epilepticus	2
Herpes Zoster	1
Herpes Simplex	1
Acute Pain	1

Clinical Trial Locations for fosphenytoin sodium

Trials by Country

Trials by Country for fosphenytoin sodium
Location	Trials
Japan	13
Pakistan	1

Clinical Trial Progress for fosphenytoin sodium

Clinical Trial Phase

Clinical Trial Phase for fosphenytoin sodium
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
N/A	1

Clinical Trial Status

Clinical Trial Status for fosphenytoin sodium
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1

Clinical Trial Sponsors for fosphenytoin sodium

Sponsor Name

Sponsor Name for fosphenytoin sodium
Sponsor	Trials
Shaheed Zulfiqar Ali Bhutto Medical University	1
Institute of Medical Sciences of the Banaras Hindu University (BHU),India	1
Banaras Hindu University	1

Sponsor Type

Sponsor Type for fosphenytoin sodium
Sponsor	Trials
Other	3
Industry	1

Fosphenytoin Sodium: Clinical Trials Update, Market Analysis, and 2026-2031 Projection

Last updated: April 29, 2026

What is the current clinical and regulatory status for fosphenytoin sodium?

Fosphenytoin sodium is an intravenous prodrug of phenytoin used in acute settings where rapid parenteral seizure control is needed. Clinical development is largely historical for the core product; the current “update” landscape is dominated by post-approval activities: safety updates, label maintenance, and periodic trial re-evaluations rather than new pivotal efficacy studies.

Clinical trials landscape (current actionable view)

No major, ongoing late-stage (Phase 3) development programs for fosphenytoin sodium are evident in the global trial registries as a driver of near-term clinical-cycle value. The market’s clinical demand is sustained by established practice patterns and guideline-consistent use for status epilepticus and urgent seizure management.

Regulatory and label maintenance

Key constraints shaping market access are:

• IV conversion to phenytoin and related safety management (cardiac monitoring, infusion rate controls, hypersensitivity and tissue injury mitigation).
• Controlled administration requirements that keep use concentrated in emergency departments, inpatient neurology pathways, and procedural settings rather than broad outpatient infusion use.

Implication for R&D and commercialization: the product’s value chain is maturity-driven, not innovation-driven. Near-term differentiation is more likely to come from formulation/device support, supply reliability, and payer contracting than from new clinical efficacy claims.

---

Which evidence base supports current use?

Fosphenytoin sodium’s clinical role is anchored in comparative pharmacokinetics and established seizure management standards for parenteral phenytoin alternatives.

Mechanism and practical pharmacology

• Fosphenytoin sodium is converted in vivo to phenytoin.
• It allows parenteral dosing with a different tolerability profile versus some phenytoin presentations, which supports IV use when immediate seizure control is required.

Real-world clinical endpoints that matter to payers and hospitals

Across hospital procurement and clinical governance, decisioning typically centers on:

• Time to therapeutic effect in urgent seizure states
• Safety handling (infusion protocols, monitoring burden, rate limits)
• Operational fit in IV dosing workflows and emergency protocols

---

How does the market work: demand drivers, buying centers, and channel structure?

Where demand concentrates

Fosphenytoin sodium demand is tied to:

• Inpatient and ED seizure pathways
• ICU and neurological emergency care
• Procedural sedation and neurology infusion protocols where urgent IV anticonvulsant coverage is required

This concentrates volumes in hospital formularies, not office-based infusion centers.

Buying centers

• Hospital pharmacy and therapeutics committees
• Emergency medicine and neurology leadership
• Procurement teams optimizing contract pricing and supply assurance

Competitive set (substitution dynamics)

Substitution typically occurs within the broader parenteral antiseizure class. The most meaningful competitive pressure is from:

• Other IV antiseizure medicines used for status epilepticus (selection depends on local protocols, formulary history, and adverse event management preferences)
• Alternative formulations and conversion to oral therapy once patients stabilize

---

What is the market size and growth outlook for fosphenytoin sodium?

A precise global market size requires current proprietary datasets, but the direction and projection can be stated from structural market realities: mature product, likely generic competition in many markets, and hospital-channel concentration.

Demand growth logic (2026-2031)

• Incidence-driven baseline demand: status epilepticus and acute seizure presentations are not disappearing; they are stable.
• Formulary substitution risk: growth is capped because competing IV antiseizure options can displace fosphenytoin in some protocols.
• Supply and pricing dynamics: generic competition compresses unit pricing, while supply reliability affects contract wins.

Growth expectation (directional)

For 2026-2031, the market is expected to:

• Grow at or near low single-digit CAGR in value in markets where generic share stabilizes
• Show slower value growth than volume due to continued pricing pressure
• Maintain stable-to-gradual volume growth driven by hospital volume and adherence to IV seizure protocols

---

What is the 2026-2031 projection for volume, revenue, and pricing?

Because fosphenytoin sodium is mature and frequently generic, projection ranges should be tied to two variables: unit pricing erosion and steady clinical demand.

Revenue mechanics

Revenue over 2026-2031 will be driven by:

• Unit price trend: downward pressure from generic competition
• Volume stability: tied to emergency/inpatient antiseizure utilization
• Contract churn: influenced by tender cycles and supplier reliability

Pricing pressure framework

• Expect continued margin compression and periodic procurement-driven price adjustments.
• Reimbursement and budget impact dynamics favor the lowest total cost option that meets seizure protocol requirements.

Projection bands (market behavior targets)

• Value CAGR: low single-digit to mid single-digit in stronger markets; lower where procurement is more aggressive
• Volume CAGR: low single-digit, with periodic dips in line with protocol shifts to competing agents

---

Where are the highest-value commercial levers?

1) Contract strategy and formulary retention

For a mature IV antiseizure product, formulary retention depends on:

• Reliable supply and short lead times
• Consistency with institutional status epilepticus protocols
• Pharmacy handling ease and stability in IV workflow

2) Pharmacovigilance and label compliance as a procurement gate

Safety administration requirements (infusion protocols, monitoring, and handling) determine whether hospitals keep fosphenytoin on formulary.

3) Patient throughput and protocol alignment

Hospitals reduce time-to-treatment and standardize infusion workflows; products that fit these protocols win repeat contracting.

---

What risks could change the projection?

Protocol displacement

If guideline committees or local neurology pathways increase preference for competing IV antiseizure agents, fosphenytoin volumes can decline even if total seizure presentations remain stable.

Shortages or manufacturing constraints

IV products are sensitive to supply interruptions; any sustained supply shock can increase customer churn in tender environments.

Regulatory and safety communications

Any material safety communication that changes administration burden or contraindications can reduce adoption.

---

What investment or R&D actions make sense in a mature-product market?

In mature IV prodrug antiseizure space, “R&D” usually means:

• Formulation improvements (stability, packaging)
• Manufacturing process robustness (reduce batch failure risk)
• Label-expanding studies only if they create new claims that shift hospital pathways

But the clinical-cycle value is limited unless a meaningful new indication, dosing optimization, or differentiated tolerability claim is achieved.

---

Key Takeaways

• Fosphenytoin sodium is a mature IV antiseizure prodrug product whose near-term value is driven by hospital formulary retention, procurement cycles, and supply reliability rather than new late-stage clinical trials.
• Clinical demand concentrates in ED and inpatient seizure pathways; adoption is tied to protocol alignment and controlled administration requirements.
• The 2026-2031 market outlook is consistent with low single-digit value growth shaped by continued pricing pressure from generic competition, with relatively steadier volume demand.
• The main upside levers are contract wins and supply assurance; the main downside risks are protocol displacement and supply interruptions.

---

FAQs

1) Is fosphenytoin sodium seeing new late-stage clinical development?

No clear evidence supports a major ongoing late-stage development pipeline as a near-term market catalyst; the product is dominated by post-approval maintenance dynamics.

2) What drives hospital demand for fosphenytoin sodium?

Time-to-treatment needs in acute seizure states, alignment with status epilepticus protocols, and workable IV administration requirements for pharmacy workflows.

3) How does generic competition affect pricing through 2031?

It typically compresses unit price over time, turning revenue growth into a function of volume stability and contract pricing, rather than premium pricing power.

4) What are the biggest substitution risks?

Shifts toward alternative IV antiseizure agents in guideline updates and local protocol retooling can reduce fosphenytoin utilization.

5) Where can commercialization teams create differentiation?

Supply reliability, contract positioning, and ensuring smooth administration compliance in hospital settings.

---

References

[1] FDA. “Label information for fosphenytoin sodium (prodrug of phenytoin).” U.S. Food and Drug Administration, accessed 2026-04-29.
[2] DailyMed. “Fosphenytoin Sodium Injection Prescribing Information.” U.S. National Library of Medicine, accessed 2026-04-29.
[3] Lexicomp / Clinical guidance summaries on status epilepticus antiseizure therapy. Accessed 2026-04-29.